Summary of Product Characteristics, Infanrix(R)-IPV+Hib. https://www.medicines.org. uk/emc/medicine/28678. Accessed March 2015.European Medicines Agency. Summary of Product Characteris- tics, 2010. EMA web site. Available at: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_...
由欧洲药品管理局(EMA)发布的关于Guideline on the summary of product characteristics for anthelmintics(驱虫药产品特性总结指南),来源于药智数据政策法规数据库。
European Public Assessment Report (EPAR) and Sum- mary of Product Characteristics Epoetin Alfa Hexal. Avail- able: http://www.emea.europa.eu/humandocs/Hu- mans/EPAR/epoetinalfahexal/epoetinalfahexal.htm. Accessed september 29, 2007Exjade. European Public Assessment Report (EPAR) - EMEA. www....
Lasix belongs to a class of diuretics, it is prescribed in patients with swelling caused by congestive heart failure. Active Ingredient:Furosemide Availability:In Stock (28 packs) View all Analogs of: Lasix Furosemide View all Other names of Lasix: ...
For more extensive recommendations, please refer to the individual summary of product characteristics. Table 3 Side effects of lipid-lowering agents Full size table Recommendation for when to stop lipid-lowering agents CVD is prevalent in older people; however, evidence for risk reduction by lipid ...
Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014) Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014)Control strategyCriticalityDesign spaceDevelopment... G Cook,G France,O Holte,... - 《Pda Journal of ...
Xeljanz (tofacitinib): sum- mary of product characteristics. 2022. https://www.ema. europa.eu/en/documents/product-information/xeljanz-epar- product-information_en.pdf Accessed June 2, 2022. 34. Charles-Schoeman C, Buch M, Dougados M, et al. Risk factors for ...
These data highlight the importance of considering myeloma disease biology characteristics such as high-risk cytogenetics when attempting to determine the clinical significance of MRD-negative results and risk of relapse 14, 15, 16, 17. BMT CTN 0702, 1302, 1401 Theresa Hahn provided an overview ...
On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior system...
apparent in the first 2–3 years, and thus, their absence in very young children should not rule out a possible diagnosis. The US Centers for Disease Control and Prevention Web Page [26] list some of the following characteristics as possible “Red Flags” for autism in toddlers (see Table...